Plain-English translation of NCT06178198 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a treatment called Yttrium-90 ablative radioembolization for people with large liver cancer tumors (larger than 8 centimeters). The treatment delivers radioactive microspheres directly to the tumor and surrounding area to destroy the cancer while trying to preserve as much healthy liver as possible. Researchers want to see if this approach can effectively treat large liver cancers while keeping patients safe.
Large liver cancers are challenging to treat, and this medication offers a way to deliver a curative dose of radiation directly to the tumor with minimal damage to healthy liver tissue—an approach that may help patients who aren't candidates for surgery or other standard treatments.
You likely qualify if…
You likely don't qualify if…
You will receive the Yttrium-90 treatment delivered through a catheter placed in your liver's blood vessel—a procedure performed by an interventional radiologist. After treatment, you'll have follow-up imaging scans and blood tests to monitor how well the cancer responds and to check for any side effects. The study will track your progress over two years, with regular clinic visits to ensure your safety and evaluate whether the treatment is working.
AI-generated summary from trial data · Aug 26, 2026 · Not medical advice
South Korea